Sandeep Garg
Non-Alcoholic fatty liver disease can occur in obese and lean patients. Diabetes, obesity, and hypothyroidism are major treatable risk factors which can prevent the progression of NAFLD to NASH and CLD. liver biopsy is considered as the gold standard for diagnosing NASH. Fibroscan a noninvasive technique is now being routinely used to detect the fibrosis of the liver. However, this facility is not available at every hospital. NAFLD fibrosis score and novel biomarkers cytokeratin 18 are being investigated as a marker of fibrosis. In this observational crosssectional study, we tried to find out the NAFLD fibrosis score, fibroscan values in 30 overweight (BMI> 23.5kg/ m2) and obese (BMI >28.5kg/ m2) NAFLD patients out of total 50 NAFLD patients diagnosed on the basis of ultrasonography. Blood tests including hemogram, KFT???s, LFT???s, lipid profile and ultrasonography and fibroscan were done in all cases. A value of > 0.676 was taken as significant fibrosis, -1.455 to ??? 0.675 as intermediate fibrosis, < -1.455 as absence of fibrosis. The mean age was 46.50�12.33years. There were 8 (26.7%) males and 22 (73.3%) females. The mean BMI was 30.08�5.27. The mean ALT and AST was 54.17�27.49IU/L and 47.0�21.92IU/L respectively. The mean total cholesterol and triglyceride were 181.67�49.13 and 199.63�34.67 respectively. The mean TSH was 5.87�5.09mIU/L. The prevalence of hypothyroidism and diabetes was 11(36.6%) and 20(66%) respectively. Mean NAFLD score was -1.144�1.47 and the fibroscan score was 7.5067�2.25. Based on the NAFLD fibrosis score significant, intermediate and no fibrosis was observed in 6.7%, 56.7%, and 36.7% respectively.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 